BCL2L11 and cancer: The complexity of response to Fsk–IBMX can be explained by MAPK-driven BIM proapoptotic signaling and provides the rationale for combining cAMP agonists with current treatments targeting key cancer signaling pathways, including components of receptor tyrosine kinase (RTK) pathways that transmit signals via MAPK.